Amgen Inc. (AMGN) – Financial and Strategic SWOT Analysis Review

Amgen Inc. (AMGN) – Financial and Strategic SWOT Analysis Review Cover

Single Licence: $125

Buy Now
customer(s) bought this report
BUY WITH CONFIDENCE

Shopping on CFDMaster.com is Safe and Secure. GUARANTEED!
All information is encrypted and handled by PayPal.com

Need Assistance?
Have you got questions about this report? Why not speak to one of our advisors. Email us at business@cfdmaster.com or call us at +61 (02) 8011 3208
# Pages
Market
Country
Single User
Site License
Enterprisewide
76
Pharmaceuticals and Healthcare
United States

Amgen Inc. (AMGN) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

– Business description – A detailed description of the company’s operations and business divisions.
– Corporate strategy – Analyst’s summarization of the company’s business strategy.
– SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
– Company history – Progression of key events associated with the company.
– Major products and services – A list of major products, services and brands of the company.
– Key competitors – A list of key competitors to the company.
– Key employees – A list of the key executives of the company.
– Executive biographies – A brief summary of the executives’ employment history.
– Key operational heads – A list of personnel heading key departments/functions.
– Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
– Key manufacturing facilities – A list of key manufacturing facilities of the company.
– Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
– Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Amgen Inc. (Amgen) is a biotechnology company. It undertakes the discovery, development, manufacture and commercialization of innovative human therapeutics. The company pioneered the development of new products based on advances in recombinant DNA and molecular biology. It offers medicines for the treatment of cancer, rheumatoid arthritis, kidney disease, bone disease and many other serious illnesses. Amgen’s R&D organization has expertise in multiple treatment modalities, antibodies, large-molecule proteins and small molecules. The company’s key products include Neulasta (pegfilgrastim); Neupogen (filgrastim) indicated for cancer treatment; Enbrel (entanercept) for treating rheumatoid arthritis; Epogen (Erythropoietic Stimulating Agents); Aranesp (darbepoetin alfa) to treat anemia associated with chronic kidney disease and in cancer; and Prolia (denosumab) used in the treatment of osteoporosis in postmenopausal women among others. Its product pipeline focuses on treating conditions such as ovarian cancer, heart disease, migraine and schizophrenia. The company has research and development (R&D) facilities in the US, Canada, the UK, Germany and Iceland. Amgen is headquartered in Thousand Oaks, California, the US.

The company’s operates with the strategic intent of launching innovative drugs to combat serious illnesses. In lieu of this the company recently in December 2014, launched Blincyto (blinatumomab) for the treatment Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

Amgen Inc. Key Recent Developments

Mar 10, 2015: Amgen To Shut Down South San Francisco Facility
Mar 04, 2015: Amgen Announces 2015 Second Quarter Dividend
Jan 29, 2015: Amgen, The Familial Hypercholesterolemia Foundation And Stanford Medicine Launch FIND FH Initiative To Improve Diagnosis And Care For People With Familial Hypercholesterolemia
Jan 27, 2015: Amgen’s 2014 Revenues Increased 7 Percent To $20.1 Billion And Adjusted Earnings Per Share (EPS) Increased 14 Percent To $8.70
Jan 12, 2015: Amgen and MD Anderson Announce Agreement to Develop BiTE Therapies for Myelodysplastic Syndrome

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
– The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
– The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
– Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
– Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
– Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company



Table of Contents

Section 1 – About the Company 6
Amgen Inc. – Key Facts 6
Amgen Inc. – Key Employees 7
Amgen Inc. – Key Employee Biographies 9
Amgen Inc. – Major Products and Services 10
Amgen Inc. – Pharmaceutical Pipeline Products Data 12
Amgen Inc., Pipeline Products by Therapy Area 12
Amgen Inc., Pipeline Products by Development Phase 13
Amgen Inc. – History 22
Amgen Inc. – Company Statement 29
Amgen Inc. – Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Amgen Inc. – Key Manufacturing Facilities 38
Joint Venture 38
Section 2 – Company Analysis 39
Amgen Inc. – Business Description 39
Amgen Inc. – Corporate Strategy 41
Amgen Inc. – SWOT Analysis 42
SWOT Analysis – Overview 42
Amgen Inc. – Strengths 42
Strength – Products Covering Various Therapeutic Areas 42
Strength – Focused R&D Activities 42
Strength – Sound Performance of Lead Products 42
Amgen Inc. – Weaknesses 43
Weakness – Termination of Development Programs 43
Weakness – Loss of Exclusivity: Neupogen 43
Weakness – Patent Infringement Lawsuit 43
Amgen Inc. – Opportunities 44
Opportunity – Promising Product Pipeline 44
Opportunity – Branded Biosimilars Growth Potential 44
Opportunity – Strategic Agreements 44
Amgen Inc. – Threats 45
Threat – Competitive Pressures 45
Threat – Concentration of Sales – Wholesaler Distributors 45
Threat – Influx of Generics 45
Amgen Inc. – Key Competitors 46
Section 3 – Company Financial Ratios 47
Financial Ratios – Capital Market Ratios 47
Financial Ratios – Annual Ratios 48
Performance Chart 50
Financial Performance 50
Financial Ratios – Interim Ratios 51
Financial Ratios – Ratio Charts 52
Section 4 – Company’s Lifesciences Financial Deals and Alliances 53
Amgen Inc., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 53
Amgen Inc., Pharmaceuticals & Healthcare, Deals By Type, 2009 to YTD 2015 54
Amgen Inc., Medical Equipment, Deals By Year, 2009 to YTD 2015 55
Amgen Inc., Medical Equipment, Deals By Type, 2009 to YTD 2015 56
Amgen Inc., Recent Deals Summary 57
Section 5 – Company’s Recent Developments 58
Mar 10, 2015: Amgen To Shut Down South San Francisco Facility 58
Mar 04, 2015: Amgen Announces 2015 Second Quarter Dividend 59
Jan 29, 2015: Amgen, The Familial Hypercholesterolemia Foundation And Stanford Medicine Launch FIND FH Initiative To Improve Diagnosis And Care For People With Familial Hypercholesterolemia 60
Jan 27, 2015: Amgen’s 2014 Revenues Increased 7 Percent To $20.1 Billion And Adjusted Earnings Per Share (EPS) Increased 14 Percent To $8.70 61
Jan 12, 2015: Amgen and MD Anderson Announce Agreement to Develop BiTE Therapies for Myelodysplastic Syndrome 64
Dec 22, 2014: Amgen Joins With LabCentral to Support Life-Sciences and Biotech Startups in Cambridge, Massachusetts 65
Dec 17, 2014: Amgen Announces 30 Percent Increase In 2015 First Quarter Dividend 66
Dec 03, 2014: Amgen To Webcast Investor Meeting At Upcoming American Society of Hematology 56th Annual Meeting And Exposition 67
Nov 19, 2014: Amgen Opens Next-generation Biomanufacturing Facility in Singapore 68
Oct 28, 2014: Amgen Outlines Strategy, Growth Objectives And Capital Allocation Plans 69
Section 6 – Appendix 72
Methodology 72
Ratio Definitions 72
About GlobalData 76
Contact Us 76
Disclaimer 76



List of Tables
Amgen Inc., Key Facts 6
Amgen Inc., Key Employees 7
Amgen Inc., Key Employee Biographies 9
Amgen Inc., Major Products and Services 10
Amgen Inc., Number of Pipeline Products by Therapy Area 12
Amgen Inc., Number of Pipeline Products by Development Stage 13
Amgen Inc., Pipeline Products By Therapy Area and Development Phase 14
Amgen Inc., History 22
Amgen Inc., Other Locations 31
Amgen Inc., Subsidiaries 34
Amgen Inc., Key Manufacturing Facilities 38
Amgen Inc., Joint Venture 38
Amgen Inc., Key Competitors 46
Amgen Inc., Ratios based on current share price 47
Amgen Inc., Annual Ratios 48
Amgen Inc., Interim Ratios 51
Amgen Inc., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 53
Amgen Inc., Pharmaceuticals & Healthcare, Deals By Type, 2009 to YTD 2015 54
Amgen Inc., Medical Equipment, Deals By Year, 2009 to YTD 2015 55
Amgen Inc., Medical Equipment, Deals By Type, 2009 to YTD 2015 56
Amgen Inc., Recent Deals Summary 57
Currency Codes 72
Capital Market Ratios 72
Equity Ratios 73
Profitability Ratios 73
Cost Ratios 74
Liquidity Ratios 74
Leverage Ratios 75
Efficiency Ratios 75



List of Figures
Amgen Inc., Pipeline Products by Therapy Area 12
Amgen Inc., Pipeline Products by Development Phase 13
Amgen Inc., Performance Chart (2010 – 2014) 50
Amgen Inc., Ratio Charts 52
Amgen Inc., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 53
Amgen Inc., Pharmaceuticals & Healthcare, Deals by Type, 2009 to YTD 2015 54
Amgen Inc., Medical Equipment, Deals By Year, 2009 to YTD 2015 55
Amgen Inc., Medical Equipment, Deals by Type, 2009 to YTD 2015 56

Report Delivery

PDF SWOT Analysis Report An Electronic PDF copy of this Report will be sent to you via email.

Please allow up to 2 business days for the reports to arrive to your mailbox as some of our publishers prefer to send you the reports directly.

Purchase this Report today

Price: $125

Report Licences Explanation

* Single User: Electronic PDF copy delivered via email. Report can be used by individual purchaser only.

* Site License: Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.

* Enterprise Wide License: Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.

If you require a Site License or Enterprise Wide License please contact us to issue you an invoice.

Customers who Viewed this Report also Viewed

Risk warning: Your capital may be at risk. CFD trading is suitable for experienced traders and not beginners.